Myocardial ischemia or cardiac ischemia is a medical condition characterized by a partial or complete blockage of the heart’s arteries thus, reducing the flow of blood to the heart. The treatment of myocardial ischemia includes medications and surgeries. Angina pectoris, fatigue, sweating, and others are some of the common symptoms of the disease. The increasing prevalence of coronary artery disease is a major driver for the market growth. From 2012 to 2013, the Heart U.K. stated that there were approximately 404,000 hospital admissions due to coronary heart diseases in England. Moreover, the increasing cases of diabetes and growing obese population boost the market growth. In 2017, according to the World Health Organization, the number of people who had diabetes in 2014 was estimated to be about 422 million. Moreover, according to the Australian Institute of Health and Welfare, approximately two-thirds, i.e., 63% of the Australian population who aged 18 or above was estimated to be overweight or obese from 2014–2015. However, factors such as lack of awareness, low per capita healthcare expenditure in the low- and middle-income countries, and the high cost of research and development coupled with stringent government policies for clinical trials and development of new drugs are estimated to restrain the market growth during the forecast period.
Global Myocardial Ischemia Market Is Expected To Grow At An Approximate CAGR Of 6.1% During The Forecast Period.
Get Sample copy with Latest Advancement @ https://www.marketresearchfuture.com/sample_request/5811 .
Baxter (U.S.), Boston Scientific Corporation (U.S.), Taxus Cardium. (U.S.), ViroMed Co. Ltd. (South Korea), Atrium (U.S.), Bayer AG (Germany), Novartis AG (Switzerland), Daiichi Sankyo Company Limited (Japan), Boehringer Ingelheim International GmbH (Germany), Sandoz International GmbH (Germany), AstraZeneca (U.K), Janssen Global Services, LLC (U.S.), Merck & Co., Inc. (U.S.), and others
The global myocardial ischemia market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of type, the market is segmented into symptomatic and asymptomatic.
On the basis of diagnosis, the market is categorized into imaging test and stress test. The imaging segment is sub-segmented into Electrocardiogram (ECG), echocardiogram, nuclear scan, coronary angiography, cardiac CT scan, and others.
On the basis of treatment, the market is segmented into medication and surgery. The medication segment is sub-segmented into antiplatelet agents, glycoprotein IIb/IIIa inhibitors, antithrombotic agents, beta-adrenergic blockers, Angiotensin-Converting Enzyme (ACE) inhibitors, angiotensin-receptor blockers, thrombolytics, analgesics, and others. The antiplatelet agents segment is segmented into aspirin, vorapaxar, clopidogrel, and others. The glycoprotein IIb/IIIa inhibitors segment is sub-segmented into abciximab, tirofiban, eptifibatide, and others. The antithrombotic agents segment is sub-segmented into heparin, bivalirudin, enoxaparin, and others. The beta-adrenergic blockers segment is sub-segmented into metoprolol, esmolol, and others. The Angiotensin-Converting Enzyme (ACE) inhibitors segment is sub-segmented into enalapril, captopril, lisinopril, and others. The angiotensin-receptor blockers are sub-segmented into candesartan, valsartan, and others. The thrombolytics segment is sub-segmented into tenecteplase, alteplase (t-PA) and others. The analgesics segment is sub-segmented into morphine sulfate, ketobemidone hydrochloride, and others. The surgery segment is sub-segmented into angioplasty and stenting, coronary artery bypass surgery, and enhanced external counterpulsation.
On the basis of end-user, the market is segmented into hospitals and clinics, diagnostic centers, pharmacies, academic institutes, and others.
The Americas dominates the global myocardial ischemia market due to a well-developed healthcare sector and increasing prevalence of coronary heart diseases. Apart from this, the changing lifestyle and increasing healthcare expenditure boost the market within the Americas. Additionally, the increasing obese population and increasing smoking population contribute to the market growth.
Followed by the Americas, Europe stands second in the global myocardial ischemia market. This can be attributed to the availability of funds for research, huge patient population, and government support for research and development. On a regional basis, Europe is divided into Western Europe and Eastern Europe. Western Europe leads the market in developed economies such as Italy, the U.K., France, and others.
Asia Pacific is estimated to be the fastest growing region due to the presence of a huge patient population, continuously developing economies such as India, China, and Australia, and a continuously developing healthcare sector. According to the Indian Brand Equity Foundation in 2017, the Indian healthcare sector was estimated to be one of the fastest growing industries and is expected to reach USD 280 billion by 2020.
On the other hand, the Middle East and Africa has the least share in the global myocardial ischemia market. The presence of poor economy, lack of healthcare services, and stringent government policies, especially within the African region make the regional market to lag. A majority of the market of the Middle East and Africa is estimated to be held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure.
Get Discount @ https://www.marketresearchfuture.com/check-discount/5811 .
The Middle Eastern region is expected to grow at a steady pace owing to factors such as rising R&D activities in the healthcare sector and extensive development of the healthcare infrastructure.
Table of Content:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.2 Scope Of The Study
2.2.1 Research Objective
Chapter 3. Research Methodology
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
List of Tables:
Table 1 Myocardial Ischemia Industry Synopsis, 2017–2023
Table 2 Global Myocardial Ischemia Market Estimates & Forecast, 2017–2023, (USD Million)
Table 3 Global Myocardial Ischemia Market, By Region, 2017–2023, (USD Million)
Table 4 Global Myocardial Ischemia Market, By Type, 2017–2023, (USD Million)
Table 5 Global Myocardial Ischemia Market, By Diagnosis, 2017–2023, (USD Million)
Table 6 Global Myocardial Ischemia Market, By Treatment, 2017–2023, (USD Million)
Table 7 Global Myocardial Ischemia Market, By End-User, 2017–2023, (USD Million
Table 8 North America Myocardial Ischemia Market, By Type, 2017–2023, (USD Million)
Table 9 North America Myocardial Ischemia Market, By Diagnosis, 2017–2023, (USD Million)
Table 10 North America Myocardial Ischemia Market, By Treatment, 2017–2023, (USD Million)
For Any Customization on this Report, Ask to Expert @ https://www.marketresearchfuture.com/enquiry/5811 .
List of Figures:
Figure 1 Research Process
Figure 2 Segmentation For Global Myocardial Ischemia Market
Figure 3 Market Dynamics For Global Myocardial Ischemia Market
Figure 4 Global Myocardial Ischemia Market Share, By Type 2016
Figure 5 Global Myocardial Ischemia Market Share, By Diagnosis 2016
Figure 6 Global Myocardial Ischemia Market Share, By Treatment, 2016
Figure 7 Global Myocardial Ischemia Market Share, By End-User, 2016
Figure 8 Global Myocardial Ischemia Market Share, By Region, 2016
Figure 9 North America Myocardial Ischemia Market Share, By Country, 2016
Figure 10 Europe Myocardial Ischemia Market Share, By Country, 2016
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Company Name: Market Research Future
Contact Person: Akash Anand
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune –